Adam Walter‐Croneck

Author

Adam Walter‐Croneck

Medical University of Lublin ORCID

Also Known As

A Walter-Croneck, A. Walter-Croneck, A. Walter‐Croneck, Adam Walter-Croneck, Adam Walter‐Croneck

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Medical University of Lublin Medical University of Silesia Ankara University National and Kapodistrian University of Athens Dana-Farber Cancer Institute

About

Adam Walter‐Croneck is an author at Medical University of Lublin specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	859
2	Immunology	8	8	811
3	Health Sciences	4	4	81
4	Cell Biology	1	1	30
5	Cellular Therapies	1	1	30

Adam Walter‐Croneck

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma Sagar Lonial, Meletios Α. Dimopoulos, Antonio Palumbo, New England Journal of Medicine	2015	1.3K
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study Michel Attal, Paul G. Richardson, S. Vincent Rajkumar, The Lancet Hematological MalignancyMedicineImmunologyHematologyPharmacotherapy	2019	620
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study Meletios Α. Dimopoulos, Sagar Lonial, Darrell White, Blood Cancer Journal	2020	151
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <scp>ELOQUENT</scp>‐2 follow‐up and <i>post‐hoc</i> analyses on progression‐free survival and tumour growth Meletios Α. Dimopoulos, Sagar Lonial, Darrell White, British Journal of Haematology	2017	131
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, The Lancet Oncology Hematological MalignancyInterim AnalysisOncologyMarrow TransplantationTransplantation	2023	69
Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients Norbert Grząśko, Marek Hus, Andrzej Pluta, Hematological Oncology	2012	48
Role of reactive oxygen species (ROS), metalloproteinase‐2 (MMP‐2) and interleukin‐6 (IL‐6) in direct interactions between tumour cell spheroids and endothelial cell monolayer Roman Paduch, Adam Walter‐Croneck, Barbara Zdzisińska, Cell Biology International	2005	34
A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization Joanna Mańko, Adam Walter‐Croneck, Dariusz Jawniak, Pharmacological Reports Cell TherapyBone Marrow FailureOriginator G-csfMedicineStem Cell Mobilization	2014	30
Matrix metalloproteinases-1 and -2, and tissue inhibitor of metalloproteinase-2 production is abnormal in bone marrow stromal cells of multiple myeloma patients Barbara Zdzisińska, Adam Walter‐Croneck, Martyna Kandefer‐Szerszeń Leukemia Research Hematological MalignancyBone Marrow FailureMatrix Metalloproteinases-1HematologyImmunology	2008	28
Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up Meletios Α. Dimopoulos, Sagar Lonial, Darrell White, Blood	2015	28

Page 1